Cocrystals are of much interest in industrial application as well as academic research, and screening of suitable coformers for active pharmaceutical ingredients is the most crucial and challenging step in cocrystal development. Recently, machine learning techniques are attracting researchers in many fields including pharmaceutical research such as quantitative structure-activity/property relationship. In this paper, we develop machine learning models to predict cocrystal formation. We extract descriptor values from simplified molecular-input line-entry system (SMILES) of compounds and compare the machine learning models by experiments with our collected data of 1476 instances. As a result, we found that artificial neural network shows great potential as it has the best accuracy, sensitivity, and F1 score. We also found that the model achieved comparable performance with about half of the descriptors chosen by feature selection algorithms. We believe that this will contribute to faster and more accurate cocrystal development.

This research is aimed at predicting the physical stability for amorphous solid dispersion by utilizing deep learning methods. We propose a prediction model that effectively learns from a small dataset that is imbalanced in terms of class. In order to overcome the imbalance problem, our model performs a hybrid sampling which combines synthetic minority oversampling technique (SMOTE) algorithm with edited nearest neighbor (ENN) algorithm and reduces the dimensionality of the dataset using principal component analysis (PCA) algorithm during data preprocessing. After the preprocessing, it performs the learning process using a carefully designed neural network of simple but effective structure. Experimental results show that the proposed model has faster training convergence speed and better test performance compared to the existing DNN model. Furthermore, it significantly reduces the computational complexity of both training and test processes.

In recent research on the formulation prediction of oral dissolving drugs, deep learning models with significantly improved performance compared to machine learning models were proposed. However, the performance degradation due to limitations of an imbalanced dataset with a small size and inefficient neural network structure has still not been resolved. Therefore, we propose new deep learning-based prediction models that maximize the prediction performance for disintegration time of oral fast disintegrating films (OFDF) and cumulative dissolution profiles of sustained-release matrix tablets (SRMT). In the case of OFDF, we use principal component analysis (PCA) to reduce the dimensionality of the dataset, thereby improving the prediction performance and reducing the training time. In the case of SRMT, the Wasserstein generative adversarial network (WGAN), a neural network-based generative model, is used to overcome the limitation of performance improvement due to the lack of experimental data. To the best of our knowledge, this is the first work that utilizes WGAN for pharmaceutical formulation prediction. Experimental results show that the proposed methods have superior performance than the existing methods for all the performance metrics considered.

The beamforming technique has attracted considerable attention in wireless communication due to its various advantages such as interference reduction and improved wireless resource efficiency. However, the beam alignment between transmitting and receiving devices, which is fundamentally required for the beamforming, poses a significant challenge due to the continuous variability of the wireless channel. Recently, a deep learning-based technique has been proposed to predict narrow beam indices by measuring wide beams. However, there is room for improvement in the performance of the neural network architecture employed in this technique. Therefore, we suggest a novel deep learning model architecture that incorporates a channel attention module for beam training. The simulation results show a significant enhancement in performance with our scheme compared to both a state-of-the-art approach and other existing methods across all scenarios. Particularly, we confirm that even when reducing the number of wide beams used for measurement by approximately $50\%$, our proposed approach achieves a performance close to that of the state-of-the-art scheme.

Small-molecule drug design aims to generate compounds that target specific proteins, playing a crucial role in the early stages of drug discovery. Recently, research has emerged that utilizes the GPT model, which has achieved significant success in various fields to generate molecular compounds. However, due to the persistent challenge of small datasets in the pharmaceutical field, there has been some degradation in the performance of generating target-specific compounds. To address this issue, we propose an enhanced target-specific drug generation model, Adapt-cMolGPT, which modifies molecular representation and optimizes the fine-tuning process. In particular, we introduce a new fine-tuning method that incorporates an adapter module into a pre-trained base model and alternates weight updates by sections. We evaluated the proposed model through multiple experiments and demonstrated performance improvements compared to previous models. In the experimental results, Adapt-cMolGPT generated a greater number of novel and valid compounds compared to other models, with these generated compounds exhibiting properties similar to those of real molecular data. These results indicate that our proposed method is highly effective in designing drugs targeting specific proteins.

Drug–phospholipid complexing is a promising formulation technology for improving the low bioavailability of active pharmaceutical ingredients (APIs). However, identifying whether phospholipid and candidate drug can form a complex through in vitro tests can be costly and time-consuming due to the physicochemical properties and experimental environment. In a previous study, the authors developed seven machine learning models to predict drug–phospholipid complex formation, and the lightGBM model demonstrated the best performance. However, the previous study was unable to sufficiently address the degradation of test performance caused by the small size of the training data with class imbalance, and it had the limitation of considering only machine learning techniques. To overcome these limitations, we propose a new deep learning-based prediction model that employs variational autoencoder (VAE) and principal component analysis (PCA) techniques to improve prediction performance. The model uses a multi-layer one-dimensional convolutional neural network (CNN) with a skip connection to effectively capture the complex relationship between drugs and lipid molecules. The computer simulation results demonstrate that our proposed model performs better than the previous model in all performance metrics.